Finch Therapeutics Group, Inc.
FNCHOTCHealthcare● Active
$7.45
+$0.00(+0.00%)
Market Cap$11962934
P/E Ratio—
52W High$16.1
52W Low$2
Finch Therapeutics Group, Inc. (FNCH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FNCH · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.02B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.01B | $0.06B | $0.03B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.04B) | ($0.03B) |
| Gross Margin %(computed) | — | — | -539.61% | -209.08% | -329.38% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.01B | $0.05B | $0.06B | $0.03B |
| G&A Expenses | $0.00B | $0.03B | $0.04B | $0.02B | $0.01B |
| Total Operating Expenses | $0.02B | $0.03B | $0.09B | $0.08B | $0.05B |
| Operating Income | ($0.02B) | ($0.03B) | ($0.10B) | ($0.06B) | ($0.04B) |
| Operating Margin %(computed) | — | — | — | -323.68% | -510.90% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.08B) | ($0.11B) | ($0.06B) | ($0.04B) |
| Income Tax Expense | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.07B) | ($0.11B) | ($0.06B) | ($0.04B) |
| Net Margin %(computed) | — | — | — | -313.84% | -508.46% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.64 | $-46.59 | $-72.12 | $-36.72 | $-24.39 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.03B) | ($0.08B) | ($0.06B) | ($0.04B) |
| EBITDA Margin %(computed) | — | — | — | -311.27% | -500.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Finch Therapeutics Group, Inc. data
About Finch Therapeutics Group, Inc. (FNCH) Income Statement
Finch Therapeutics Group, Inc. (FNCH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, FNCH reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
FNCH · 4 questionsFinch Therapeutics Group, Inc. (FNCH) reported revenue of $0.00B for 2024, down 100.0% year-over-year.
FNCH revenueFNCH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09